Balwinder Singh

Trials

Studies that name Balwinder Singh as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:51 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06668571 · Intravenous Ketamine for Treatment-Resistant Depression

  Mayo Clinic · recruiting · Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD) · principal investigator
• Early Ph1
  NCT03573349 · Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

  Mayo Clinic · active not recruiting · Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression · principal investigator
• N/A
  NCT03066765 · LTR for Treatment of Obstructive Sleep Apnea

  Linguaflex, Inc. · completed · Obstructive Sleep Apnea · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Institutional Career Development Core
  KL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · fiscal years 2017 to 2026
  Named on NCT06668571